Table 2.
Gene ontology (GO) categories identified using IPA
| Gene ontology category | P-value range | Number of genes |
|---|---|---|
| Inflammatory response | 1.66 × 10-11 - 1.64 × 10-2 | 241 |
| Cellular development | 8.95 × 10-10 - 1.57 × 10-2 | 308 |
| Cellular growth and proliferation | 1.65 × 10-9 - 1.57 × 10-2 | 333 |
| Haematological system development and function | 1.65 × 10-9 - 1.64 × 10-2 | 279 |
| Haematopoiesis | 2.60 × 10-8 - 1.57 × 10-2 | 173 |
| Tissue morphology | 1.78 × 10-7 - 1.19 × 10-2 | 114 |
| Cellular function and maintenance | 5.44 × 10-7 - 1.65 ×10-2 | 138 |
| Cell death | 9.57 × 10-7 - 1.60 × 10-2 | 419 |
| Cell-mediated immune response | 1.06 × 10-6 - 1.25 × 10-2 | 109 |
| Connective tissue disorders | 1.72 × 10-6 - 5.94 × 10-3 | 234 |
| Immunological disease | 1.72 × 10-6 - 1.57 × 10-2 | 344 |
| Inflammatory disease | 1.72 × 10-6 - 1.28 × 10-2 | 364 |
| Skeletal and muscular disorders | 1.72 × 10-6 - 1.22 × 10-2 | 235 |
| Infectious disease | 1.82 × 10-6 - 1.17 × 10-2 | 223 |
| Cell-to-cell signalling and interaction | 8.33 × 10-6 - 1.64 × 10-2 | 210 |
| Dermatological diseases and conditions | 1.04 × 10-5 - 1.57 × 10-2 | 107 |
| Free radical scavenging | 1.23 × 10-5 - 1.23 × 10-5 | 14 |
| Molecular transport | 1.23 × 10-5 - 7.43 × 10-3 | 86 |
| Cell signalling | 2.40 × 10-5 - 7.21 × 10-5 | 133 |
| Respiratory disease | 2.86 × 10-5 - 1.24 × 10-2 | 109 |
| Cellular compromise | 3.09 × 10-5 - 1.57 × 10-2 | 41 |
| Genetic disorder | 3.39 × 10-5 - 1.64 × 10-2 | 104 |
| Immune cell trafficking | 3.51 × 10-5 - 1.64 × 10-2 | 163 |
| Humoral immune response | 5.08 × 10-5 - 1.19 × 10-2 | 78 |
| Organismal injury and abnormalities | 9.51 × 10-5 - 1.05 × 10-2 | 81 |
| Tissue development | 1.19 × 10-4 - 1.05 × 10-2 | 108 |
| Haematological disease | 1.78 × 10-4 - 1.35 × 10-2 | 162 |
| Gastrointestinal disease | 1.88 × 10-4 - 5.51 × 10-3 | 42 |
| Hepatic system disease | 1.88 × 10-4 - 1.64 × 10-2 | 89 |
| Lymphoid tissue structure and development | 1.94 × 10-4 - 5.94 × 10-3 | 5 |
| Antigen presentation | 3.42 × 10-4 -1.64 × 10-2 | 83 |
| Cellular movement | 3.58 × 10-4 - 1.63 × 10-2 | 157 |
| Vitamin and mineral metabolism | 3.59 × 10-4 - 7.21 × 10-3 | 74 |
| Antimicrobial response | 3.92 × 10-4 - 1.28 × 10-2 | 32 |
| Hypersensitivity response | 5.86 × 10-4 - 8.60 × 10-3 | 31 |
| Infection mechanism | 9.89 × 10-4 - 1.57 × 10-2 | 39 |
| Gene expression | 1.07 × 10-3 - 1.57 × 10-2 | 254 |
| Hair and skin development and function | 1.23 × 10-3 - 1.57 × 10-2 | 22 |
| Post-translational modification | 2.27 × 10-3 - 9.78 × 10-3 | 84 |
| Cancer | 2.51 × 10-3 - 1.57 × 10-2 | 385 |
| Endocrine system development and function | 2.65 × 10-3 - 2.65 × 10-3 | 21 |
| Carbohydrate metabolism | 3.77 × 10-3 - 3.77 × 10-3 | 6 |
| Cell morphology | 3.77 × 10-3 - 1.28 × 10-2 | 23 |
| Lipid metabolism | 3.77 × 10-3 - 7.43 × 10-3 | 17 |
| Neurological disease | 3.77 × 10-3 - 1.47 × 10-2 | 49 |
| Small molecule biochemistry | 3.77 × 10-3 - 7.43 × 10-3 | 23 |
| Metabolic disease | 3.91 × 10-3 - 3.91 × 10-3 | 7 |
| Embryonic development | 4.59 × 10-3 - 1.57 × 10-2 | 21 |
| Nervous system development and function | 4.59 × 10-5 - 1.18 × 10-2 | 8 |
| Reproductive system disease | 5.84 × 10-3 - 7.54 × 10-3 | 79 |
| Cell cycle | 5.94 × 10-3 - 1.18 × 10-2 | 20 |
| Endocrine system disorders | 5.94 × 10-3 - 5.94 × 10-3 | 3 |
| Opthalmic disease | 5.94 × 10-3 - 6.60 × 10-3 | 7 |
| RNA post-transcriptional modification | 6.04 × 10-3 - 6.04 × 10-3 | 13 |
| Cardiovascular system development and function | 6.68 × 10-3 - 1.30 ×10-2 | 19 |
| Cell assembly and modification | 6.68 × 10-3 - 1.28 × 10-2 | 14 |
| Organ development | 6.68 × 10-3 - 1.19 × 10-2 | 6 |
| Renal and urological system development and function | 1.18 × 10-2 - 1.30 × 10-2 | 11 |
| Reproductive system development and function | 1.18 × 10-2 - 1.18 × 10-2 | 4 |
The top ranking GO categories identified by IPA are listed according to P-values. P-value ranges are based on subcategory P-values within each parent term.